These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 36496454)

  • 21. Repurposing metformin to treat age-related neurodegenerative disorders and ischemic stroke.
    Sharma S; Nozohouri S; Vaidya B; Abbruscato T
    Life Sci; 2021 Jun; 274():119343. PubMed ID: 33716063
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin.
    Hsu CC; Wahlqvist ML; Lee MS; Tsai HN
    J Alzheimers Dis; 2011; 24(3):485-93. PubMed ID: 21297276
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metformin.
    Bailey CJ; Turner RC
    N Engl J Med; 1996 Feb; 334(9):574-9. PubMed ID: 8569826
    [No Abstract]   [Full Text] [Related]  

  • 24. Treatment of non-insulin-dependent diabetes mellitus with metformin.
    Guthrie R
    J Am Board Fam Pract; 1997; 10(3):213-21. PubMed ID: 9159660
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dementia Diagnosis Is Associated with Changes in Antidiabetic Drug Prescription: An Open-Cohort Study of ∼130,000 Swedish Subjects over 14 Years.
    Secnik J; Xu H; Schwertner E; Hammar N; Alvarsson M; Winblad B; Eriksdotter M; Garcia-Ptacek S; Religa D
    J Alzheimers Dis; 2020; 76(4):1581-1594. PubMed ID: 32741836
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The risk of overall mortality in patients with Type 2 diabetes receiving different combinations of sulfonylureas and metformin: a retrospective analysis.
    Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Nutter B; Jain A; Atreja A; Zimmerman RS
    Diabet Med; 2012 Aug; 29(8):1029-35. PubMed ID: 22248043
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Risk of TB in Patients With Type 2 Diabetes Initiating Metformin vs Sulfonylurea Treatment.
    Pan SW; Yen YF; Kou YR; Chuang PH; Su VY; Feng JY; Chan YJ; Su WJ
    Chest; 2018 Jun; 153(6):1347-1357. PubMed ID: 29253553
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence of hypoglycemia among a sample of sulfonylurea-treated patients with Type 2 diabetes mellitus in Argentina: The real-life effectiveness and care patterns of diabetes management (RECAP-DM) study.
    Gonzalez C; Monti C; Pinzon A; Monsanto H; Ejzykowicz F;
    Endocrinol Diabetes Nutr (Engl Ed); 2018 Dec; 65(10):592-602. PubMed ID: 30076124
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metformin vs sulfonylurea use and risk of dementia in US veterans aged ≥65 years with diabetes.
    Orkaby AR; Cho K; Cormack J; Gagnon DR; Driver JA
    Neurology; 2017 Oct; 89(18):1877-1885. PubMed ID: 28954880
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial.
    Vaccaro O; Masulli M; Nicolucci A; Bonora E; Del Prato S; Maggioni AP; Rivellese AA; Squatrito S; Giorda CB; Sesti G; Mocarelli P; Lucisano G; Sacco M; Signorini S; Cappellini F; Perriello G; Babini AC; Lapolla A; Gregori G; Giordano C; Corsi L; Buzzetti R; Clemente G; Di Cianni G; Iannarelli R; Cordera R; La Macchia O; Zamboni C; Scaranna C; Boemi M; Iovine C; Lauro D; Leotta S; Dall'Aglio E; Cannarsa E; Tonutti L; Pugliese G; Bossi AC; Anichini R; Dotta F; Di Benedetto A; Citro G; Antenucci D; Ricci L; Giorgino F; Santini C; Gnasso A; De Cosmo S; Zavaroni D; Vedovato M; Consoli A; Calabrese M; di Bartolo P; Fornengo P; Riccardi G; ;
    Lancet Diabetes Endocrinol; 2017 Nov; 5(11):887-897. PubMed ID: 28917544
    [TBL] [Abstract][Full Text] [Related]  

  • 31. No association between metformin initiation and incident dementia in older adults newly diagnosed with diabetes.
    Wu CY; Wang C; Saskin R; Shah BR; Kapral MK; Lanctôt KL; Herrmann N; Cogo-Moreira H; MacIntosh BJ; Edwards JD; Swardfager W
    J Intern Med; 2024 Jan; 295(1):68-78. PubMed ID: 37747779
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Heterogeneous treatment effects of metformin on risk of dementia in patients with type 2 diabetes: A longitudinal observational study.
    Tang H; Guo J; Shaaban CE; Feng Z; Wu Y; Magoc T; Hu X; Donahoo WT; DeKosky ST; Bian J
    Alzheimers Dement; 2024 Feb; 20(2):975-985. PubMed ID: 37830443
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes.
    Johnson JA; Majumdar SR; Simpson SH; Toth EL
    Diabetes Care; 2002 Dec; 25(12):2244-8. PubMed ID: 12453968
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination therapy with insulin glargine plus metformin but not insulin glargine plus sulfonylurea provides similar glycemic control to triple oral combination therapy in patients with type 2 diabetes uncontrolled with dual oral agent therapy.
    Hollander P; Sugimoto D; Vlajnic A; Kilo C
    J Diabetes Complications; 2015; 29(8):1266-71. PubMed ID: 26281972
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is metformin beneficial for heart failure in patients with type 2 diabetes?
    Packer M
    Diabetes Res Clin Pract; 2018 Feb; 136():168-170. PubMed ID: 29278713
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An overview of metformin in the treatment of type 2 diabetes mellitus.
    Davidson MB; Peters AL
    Am J Med; 1997 Jan; 102(1):99-110. PubMed ID: 9209206
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies.
    Thakkar B; Aronis KN; Vamvini MT; Shields K; Mantzoros CS
    Metabolism; 2013 Jul; 62(7):922-34. PubMed ID: 23419783
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis.
    Gross JL; Kramer CK; Leitão CB; Hawkins N; Viana LV; Schaan BD; Pinto LC; Rodrigues TC; Azevedo MJ;
    Ann Intern Med; 2011 May; 154(10):672-9. PubMed ID: 21576535
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term comparative safety analysis of the risks associated with adding or switching to a sulfonylurea as second-line Type 2 diabetes mellitus treatment in a US veteran population.
    Powell WR; Christiansen CL; Miller DR
    Diabet Med; 2019 Nov; 36(11):1384-1390. PubMed ID: 30343492
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Gut Microbiome, Metformin, and Aging.
    Induri SNR; Kansara P; Thomas SC; Xu F; Saxena D; Li X
    Annu Rev Pharmacol Toxicol; 2022 Jan; 62():85-108. PubMed ID: 34449247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.